Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Authors: Pfaller MA,Diekema DJ,Andes D,Arendrup MC,Brown SD,Lockhart SR,Motyl M,Perlin DS,CLSI Subcommittee for Antifungal Testing,
Address: University of Iowa, Iowa City, United States. michael-pfaller@uiowa.edu
Journal: Drug Resist Updat.

Publication: 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Epub 2011 Feb 24.

abstract

the CLSI established clinical breakpoints (CBPs) for caspofungin (CSF), micafungin (MCF) and anidulafungin (ANF) versus Candida. The same CBP (susceptible (S): MIC ≤ 2 mcg/ml; non-S: MIC > 2 mcg/ml) was applied to all echinocandins and species. More data now allow reassessment of these CBPs. We examined cases of echinocandin failure where both MICs and fks mutations were assessed; wild type (WT) MICs and epidemiological cutoff values (ECVs) for a large Candida collection; molecular analysis of fks hotspots for Candida with known MICs; and pharmacokinetic and pharmacodynamic (PK/PD) data. We applied these findings to propose new species-specific CBPs for echinocandins and Candida. Of 18 candidiasis cases refractory to echinocandins and with fks mutations, 28% (CSF), 58% (ANF) and 66% (MCF) had MICs in the S category using CBP of ≤ 2 mcg/ml, while 0-8% would be S using CBP of ≤ 0.25 mcg/ml. WT MIC distributions revealed ECV ranges of 0.03-0.25 mcg/ml for all major species except C. parapsilosis (1-4 mcg/ml) and C. guilliermondii (4-16 mcg/ml). Among Candida tested for fks mutations, only 15.7-45.1% of 51 mutants were detected using the CBP for NS of >2 mcg/ml. In contrast, a cutoff of >0.25 mcg/ml for C. albicans, C. tropicalis, C. krusei, and C. dubliniensis detected 85.6% (MCF) to 95.2% (CSF) of 21 mutant strains. Likewise, a cutoff of >0.12 mcg/ml for ANF and CSF and of >0.06 mcg/ml for MCF detected 93% (ANF) to 97% (CSF, MCF) of 30 mutant strains of C. glabrata. These data, combined with PK/PD considerations, support CBPs of ≤ 0.25 mcg/ml (S), 0.5 mcg/ml (I), ≥ 1 (R) for CSF/MCF/ANF and C. albicans, C. tropicalis and C. krusei and ≤ 2 mcg/ml (S), 4 mcg/ml (I), and ≥ 8 mcg/ml (R) for these agents and C. parapsilosis. The CBPs for ANF and CSF and C. glabrata are ≤ 0.12 mcg/ml (S), 0.25 mcg/ml (I), and ≥ 0.5 mcg/ml (R), whereas those for MCF are ≤ 0.06 mcg/ml (S), 0.12 mcg/ml (I), and ≥ 0.25 mcg/ml (R). New, species-specific CBPs for Candida and the echinocandins are more sensitive to detect emerging resistance associated with fks mutations, and better able to predict risk for clinical failure.

Related Articles
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
J Clin Microbiol. 2011
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D. J Clin Microbiol. 2011 Feb; 49(2):624-9. Epub 2010 Dec 8.
Breakthrough invasive candidiasis in patients on micafungin.
J Clin Microbiol. 2010
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. J Clin Microbiol. 2010 Jul; 48(7):2373-80. Epub 2010 Apr 26.
Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Diagn Microbiol Infect Dis. 2012
Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A, Ramani R. Diagn Microbiol Infect Dis. 2012 Aug; 73(4):365-8. Epub 2012 Jun 20.
Review In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
Enferm Infecc Microbiol Clin. 2011
Review In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
Espinel-Ingroff A, Cantón E. Enferm Infecc Microbiol Clin. 2011 Mar; 29 Suppl 2:3-9.
Review Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
Diagn Microbiol Infect Dis. 2011
Review Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, et al. Diagn Microbiol Infect Dis. 2011 Jul; 70(3):330-43. Epub 2011 May 4.
Elevated chitin content reduces the susceptibility of Candida species to caspofungin.
Antimicrob Agents Chemother. 2013
Elevated chitin content reduces the susceptibility of Candida species to caspofungin.
Walker LA, Gow NA, Munro CA. Antimicrob Agents Chemother. 2013 Jan; 57(1):146-54. Epub 2012 Oct 22.
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Antimicrob Agents Chemother. 2012
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. Antimicrob Agents Chemother. 2012 Sep; 56(9):4862-9. Epub 2012 Jul 2.
Review Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.
J Clin Microbiol. 2012
Review Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.
Pfaller MA, Diekema DJ. J Clin Microbiol. 2012 Sep; 50(9):2846-56. Epub 2012 Jun 27.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.